Skip to main content

Vanda Pharmaceuticals(VNDA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low8.91
Day High9.94
Open:8.95
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Vanda Pharmaceuticals

Select a category then submit the form to load news
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley
Tipranks
B. Riley Securities Reaffirms Their Buy Rating on Vanda (VNDA)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Vanda (VNDA), Abeona Therapeutics (ABEO)
Tipranks
Vanda Wins FDA Approval for Bysanti Antipsychotic Therapy
Stock Target Advisor
Tariff Confusion Sinks Stocks: Market Analysis for Februrary 23rd, 2026
Tariff Confusion Sinks Stocks: Market Analysis for Februrary 23rd, 2026
Tipranks
Vanda Board Approves 2025 Bonuses and 2026 Compensation
Tipranks
B. Riley Securities Keeps Their Buy Rating on Vanda (VNDA)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: AMN Healthcare Services (AMN), Vanda (VNDA) and BioMarin Pharmaceutical (BMRN)
Tipranks
Cantor Fitzgerald Keeps Their Buy Rating on Vanda (VNDA)
Tipranks
Regulatory Hurdles Cloud Vanda Pharmaceuticals’ Prospects for Bysanti and Imsidolimab FDA Approvals
Tipranks
Vanda Pharmaceuticals Balances Growth With Rising Risks
Motley Fool
Vanda (VNDA) Q4 2025 Earnings Call Transcript
Tipranks
Vanda Pharmaceuticals Advances Ponesimod Into Phase 3 Psoriasis Study: What Investors Should Know
Newsfile
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation
Tipranks
Vanda Faces FDA Setback on HETLIOZ Jet Lag Application
Tipranks
Vanda Pharmaceuticals price target raised to $14 from $11 at B. Riley
Tipranks
Cantor Fitzgerald Remains a Buy on Vanda (VNDA)
Tipranks
Vanda Wins FDA Approval for NEREUS Motion Sickness Drug
Zacks Investment Research
3 Biotech Stocks With Major 2026 Catalysts
3 Biotech Stocks With Major 2026 Catalysts
Tipranks
Cantor Fitzgerald Sticks to Their Buy Rating for Vanda (VNDA)
Tipranks
FDA Lifts Hold on Vanda’s Tradipitant Trials
Motley Fool
Should You Invest in This Under-the-Radar Weight Loss Stock?
Tipranks
H.C. Wainwright Sticks to Their Buy Rating for Vanda (VNDA)
Tipranks
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Vanda (VNDA) and Travere Therapeutics (TVTX)
Tipranks
Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges
Tipranks
Vanda Pharmaceuticals Reports Strong Sales Growth and Pipeline Progress
Tipranks
Vanda Pharmaceuticals Advances with Promising Social Anxiety Disorder Treatment Study
Tipranks
Vanda Pharmaceuticals Advances Dry Eye Treatment with VSJ-110 Study
Tipranks
Vanda Pharmaceuticals Completes Key Bioequivalence Study for Schizophrenia and Bipolar Disorder Treatment
Tipranks
Vanda Pharmaceuticals Reaches Agreement with FDA
Tipranks
H.C. Wainwright Keeps Their Buy Rating on Vanda (VNDA)

Profile

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.